ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 32 of 79 for:    "Bronchiolitis obliterans"

Use of Erythromycin in Mustard-Induced Bronchiolitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00367419
Recruitment Status : Completed
First Posted : August 22, 2006
Last Update Posted : November 5, 2008
Sponsor:
Information provided by:
Baqiyatallah Medical Sciences University

August 21, 2006
August 22, 2006
November 5, 2008
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00367419 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Use of Erythromycin in Mustard-Induced Bronchiolitis
Low-Dose Long-Term Prescription of Erythromycin in Mustard-Induced Bronchiolitis Obliterans
We looked for the effectiveness of low-dose long-term prescription of erythromycin in mustard-induced bronchiolitis obliterans
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
  • Bronchiolitis Obliterans
  • Acute Obliterating Bronchiolitis
Drug: Erythromycin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Documented chemical exposure
  • Clinical, spirometric and radiological findings were compatible with BO on High Resolution Computed Tomography (HRCT)
  • Non-responsiveness to high dose bronchodilator therapy

Exclusion Criteria:

  • Radiographic evidence of pneumonia, active tuberculosis, lung carcinoma, or an infection that necessitated the use of an antibiotic
  • History of cigarette smoking and occupational exposure to toxic agents of hypersensitivity to macrolides
  • History of treatment with a systemic antibiotic within 7 days before the start of the study
  • Any investigational medicine within 4 weeks of the study
  • History of antibiotic injection within 6 weeks before the study
  • Concomitant Theophylline or Carbamazepine, unless their serum concentrations were regularly monitored
  • Patients who were in the exacerbation phase of their respiratory complications
  • Need to use medications interact with macrolides such as Digoxin, Theophylline and Carbamazepine
  • Systemic antibiotics
  • Systemic Corticosteroids
  • Admission to the hospital
  • Abnormal kidney or liver function
Sexes Eligible for Study: Male
Child, Adult, Older Adult
Not Provided
Contact information is only displayed when the study is recruiting subjects
Iran, Islamic Republic of
 
 
NCT00367419
S-340-14-6-1-PU-02
Not Provided
Not Provided
Not Provided
Not Provided
Baqiyatallah Medical Sciences University
Not Provided
Study Director: Mostafa Ghanei, Professor Research Center of Chemical Injuries, Baqyatallah Medical Sciences University, Tehran, Iran
Baqiyatallah Medical Sciences University
March 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP